Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.
2.

Individual health services.

Schnell-Inderst P, Hunger T, Hintringer K, Schwarzer R, Seifert-Klauss VR, Gothe H, Wasem J, Siebert U.

GMS Health Technol Assess. 2011;7:Doc05. doi: 10.3205/hta000096. Epub 2011 Sep 15.

3.

Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease.

Müller-Riemenschneider F, Damm K, Meinhard C, Bockelbrink A, Vauth C, Willich SN, Greiner W.

GMS Health Technol Assess. 2009 Dec 14;5:Doc16. doi: 10.3205/hta000078.

4.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
5.

Falls prevention for the elderly.

Balzer K, Bremer M, Schramm S, Lühmann D, Raspe H.

GMS Health Technol Assess. 2012;8:Doc01. doi: 10.3205/hta000099. Epub 2012 Apr 12.

6.

Translating genomics in cancer care.

Bombard Y, Bach PB, Offit K.

J Natl Compr Canc Netw. 2013 Nov;11(11):1343-53. Review.

PMID:
24225968
7.

Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies.

Merlin T, Farah C, Schubert C, Mitchell A, Hiller JE, Ryan P.

Med Decis Making. 2013 Apr;33(3):333-42. doi: 10.1177/0272989X12452341. Epub 2012 Aug 15.

8.

Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.

Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U, Towse A, Veenstra D, Watkins J; Personalized Medicine Development and Reimbursement Working Group.

Value Health. 2012 Dec;15(8):1162-71. doi: 10.1016/j.jval.2012.05.006. Epub 2012 Sep 7.

9.

Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.

Lipworth W, Doran E, Kerridge I, Day R.

Aust Health Rev. 2014 May;38(2):160-8. doi: 10.1071/AH13240.

PMID:
24589424
10.

Just caring: assessing the ethical and economic costs of personalized medicine.

Fleck LM.

Urol Oncol. 2014 Feb;32(2):202-6. doi: 10.1016/j.urolonc.2013.09.013.

PMID:
24445288
11.

Personalized medicine: ethics for clinical trials.

Sharrer GT.

Methods Mol Biol. 2012;823:35-48. doi: 10.1007/978-1-60327-216-2_3.

PMID:
22081337
12.

The London low emission zone baseline study.

Kelly F, Armstrong B, Atkinson R, Anderson HR, Barratt B, Beevers S, Cook D, Green D, Derwent D, Mudway I, Wilkinson P; HEI Health Review Committee.

Res Rep Health Eff Inst. 2011 Nov;(163):3-79.

PMID:
22315924
14.

Bone graft substitutes for the treatment of traumatic fractures of the extremities.

Hagen A, Gorenoi V, Schönermark MP.

GMS Health Technol Assess. 2012;8:Doc04. doi: 10.3205/hta000102. Epub 2012 Jun 14.

15.

Conflicts of interest in research involving human beings.

Greco D, Diniz NM.

J Int Bioethique. 2008 Mar-Jun;19(1-2):143-54, 202-3. Review.

PMID:
18664007
16.

[Introductory remarks by chairpersons].

Kumagai S, Nobori T.

Rinsho Byori. 2013 May;61(5):419-20. Japanese.

PMID:
23947181
17.

[Rationing in German health care with particular consideration of oncology: view points of German stakeholders--a qualitative interview study].

Lange J, Gönner C, Vollmann J, Rauprich O.

Gesundheitswesen. 2015 Jan;77(1):8-15. doi: 10.1055/s-0034-1367021. Epub 2014 Apr 2. German.

PMID:
24696371
18.
19.

Over-, under- and misuse of pain treatment in Germany.

Dietl M, Korczak D.

GMS Health Technol Assess. 2011 Apr 19;7:Doc03. doi: 10.3205/hta000094.

20.

Prevention of alcohol misuse among children, youths and young adults.

Korczak D, Steinhauser G, Dietl M.

GMS Health Technol Assess. 2011;7:Doc04. doi: 10.3205/hta000095. Epub 2011 Jul 22.

Supplemental Content

Support Center